Abstract-This study evaluated the effects of a positive family history of hypertension (FHϩ) on the contributions of sympathetic nervous system (SNS) activity and insulin to blood pressure elevation (BPE). The study design was longitudinal and evaluated BP, body mass index (BMI), and fasting plasma insulin and norepinephrine (NE) levels for 10 years in 557 young, nonobese Japanese men who were normotensive at entry. FHϩ was defined as hypertension in first-degree relatives as verified by historical records or direct determination. BPE was defined as a Ն10% rise in systolic and diastolic BP over entry levels during the 10-year period. In the total group FHϩ was noted in 16%, and BPE occurred in 18% of normotensive subjects. When evaluated by FH, the prevalence of BPE was 33% in FHϩ compared with 16% in FHϪ (PϽ0.05). BP levels were greater both at entry and at year 10 in the FHϩ group. The absolute increment in plasma NE over 10 years was greater in the BPE group than in those without BPE (PϽ0.01). Of note, the rise in plasma NE levels in BPE individuals was identical in FHϩ and FHϪ subjects. Plasma insulin increments were also greater in normotensive subjects with BPE than in normotensive subjects without BPE. However, compared with NE, development of hyperinsulinemia was more pronounced in the FHϩ subjects. The results indicate that SNS hyperactivity may be a less genetically determined predictor of hypertension than is hyperinsulinemia. Because SNS changes in this initially normotensive population appeared more closely related to the development of hypertension than to hyperinsulinemia, environmental rather than genetic factors may be the main determinant of early BPE in nonobese normotensive subjects. (Hypertension. 1998;32:96-100.)
T he association of hypertension with hyperinsulinemia and SNS hyperactivity is well established. [1] [2] [3] [4] [5] [6] [7] What is less certain is whether increases in SNS activity and insulin precede or follow the development of hypertension. Increases in SNS activity and metabolic abnormalities may be closely aligned with the rise in BP. For example, in a cross-sectional study, our group found that SNS hyperactivity and abnormal blood glucose and insulin responses to glucose administration characterized the early phase of hypertension. 8 In a 10-year longitudinal study, we also noted that increases in SNS activity preceded the hyperinsulinemia and rise in BP in subjects who were normotensive at entry. 9 In the Normative Aging Study of 752 nondiabetic, middle-aged, male participants, it was also found that insulin levels and urinary NE excretion were related to BP levels. 7 The study concluded that insulin levels and urinary NE excretion were independent predictors of hypertension. In analyzing the relationship of SNS activity and insulin to the development of coronary risk in hypertension, Julius et al 10, 11 commented on the "chicken-and-egg" question of whether SNS and insulin abnormalities precede the development of hypertension. Many shortterm studies in humans have indicated that insulin administration is capable of altering SNS activity and vascular responses. [12] [13] [14] [15] [16] [17] [18] [19] Two important considerations in the role for insulin and SNS activity in BP are the effects of body weight and genetic influences. One method to study genetic influences of a trait (eg, BP) in humans is to select unaffected individuals with a family history of the trait. Several studies using this design have shown altered insulin sensitivity and hyperinsulinemia in normalweight or obese normotensive offspring of hypertensive parents. 20 -30 However, most of the study protocols on genetic influences used a cross-sectional rather than a longitudinal design. Some studies noted that body weight was a factor in FHϩ. 24, 29, 30 The present study extends previously reported data 9 to examine, on a longitudinal basis, the influence of an FHϩ on insulin, plasma NE, and rise in BP (ie, BPE) for 10 years in subjects who were normotensive at entry. The protocol measured BP, pulse, BMI, and plasma NE and insulin for 10 years in young (Ͻ50 years), nonobese (BMI Ͻ26.0 kg/m 2 ), normotensive Japanese men. Data analysis compared these variables in those with and without BPE who were further subdivided into FHϩ and FHϪ groups.
Methods

Subjects
A cohort of 1064 young normotensive Japanese men working in a factory in Osaka, Japan, were studied on an annual basis. Excluded were 41 with obesity (BMI Ն26.0 kg/m 2 ), 22 with diabetes mellitus (HbA1c Ͼ6.0%), 39 with a strong family history of diabetes, and 13 with heart disease. Additional exclusions were 241 subjects who were taking medications other than antihypertensive drugs, 3 subjects who had significant changes in BMI (Ն1.0 kg/m 2 ), and 158 subjects for whom a family history of hypertension was unknown. Consequently, 557 normotensive subjects were included in the study. At entry, individuals were young (meanϮSD age, 39.1Ϯ2.1 years) and nonobese (BMI, 22.3Ϯ1.2 kg/m 2 ). Normal BP was defined as the mean of three supine readings of Յ140/90 mm Hg. FHϩ was defined as at least one parent's having hypertension documented by previous medical records or by direct BP measurements in the parents. FHϪ was defined as both parents' being normotensive. Informed consent was obtained from each subject as approved by the Ethics Committee of Osaka University Medical School.
Protocol
After subjects had fasted for 12 hours overnight, BP, pulse rate, and BMI were determined. After the subjects had rested for 30 minutes in the supine position in a quiet room, venous blood was taken for blood glucose, plasma insulin, and NE levels. Supine BP was measured three times and then averaged. BP and pulse rate were measured with an automated sphygmomanometer (TM-2711 or TM-2713, A&D), which was standardized against a mercury sphygmomanometer. Plasma NE was measured by the fluorometric method after separation by high-performance liquid chromatography. In this assay, the intra-assay CV was 2.1%, the interassay CV 3.6%, and sensitivity 0.01 to 20 ng/mL. Plasma immunoreactive insulin was measured by a standard radioimmunoassay method (insulin RIABEAD II, Dinabott). The intra-assay CV was 1.9%, the interassay CV 2.2%, and sensitivity 0.75 to 300 mU/mL. Blood glucose was measured by autoanalyzer (Hitachi-7050).
Statistical Analyses
Values are shown as meanϮSD. Changes in variables within each group and differences among groups were examined by two-way ANOVA. Dunnett's test was used to determine whether the differences of the mean at 10 years from values at entry were significant among groups. The statistical analyses to compare prevalence of BPE and FHϩ were performed by 2 test. Values of PϽ0.05 were considered significant.
Results
Of the total group, 87 of the 557 subjects (16%) were found to be FHϩ, and 103 of the 557 (18%) had a BPE during the study period. When analyzed by family history, the prevalence of BPE was 33% (29/87) in FHϩ subjects versus 16% (74/470) in FHϪ subjects (PϽ0.05). Figure 1 shows the meanϮSD systolic and diastolic levels of BP (top), mean age (middle), and mean BMI (bottom) at entry and at year 10 grouped by FHϪ (left) and FHϩ (right). These four study groups were then further subdivided into those that had a BPE (Ն10% over baseline) and those that did not (Ͻ10% over baseline) at 10 years.
Mean BP levels at entry in FHϩ was greater than FHϪ regardless of the BP change over time. In addition, in FHϩ, those with BPE had higher BP levels at entry and at year 10 compared with those without BPE. In FHϪ subjects, BP levels at entry were similar regardless of future BPE. Mean age did not differ in the four study groups at entry as well as at year 10 ( Figure 1, middle) . BMIs did not differ from each other at entry and year 10, nor did they change significantly in any study group (Figure 1, bottom) . Figure 2 shows mean fasting blood glucose (top), fasting plasma insulin (middle), and plasma NE (bottom) levels at entry and at year 10 in subjects subdivided by FHϪ (left) and FHϩ (right). The groups were further subdivided by the presence (Ն10%) or absence (Ͻ10%) of BPE. Fasting blood glucose levels were greater in FHϩ than in FHϪ subjects (Figure 2, top) . In FHϩ who had a BPE, glucose levels were higher at year 10 compared with those at entry (PϽ0.05). Mean fasting plasma insulin levels increased significantly from entry to year 10 in the four study groups. These increments were greater in the BPE groups (Figure 2 , middle). At entry and year 10, mean insulin levels were highest in the FHϩ groups regardless of BPE (PϽ0.05). In general, 
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BPE ϭ blood pressure elevation BMI ϭ body mass index CV ϭ coefficient of variation FHϩ ϭ family history of hypertension FHϪ ϭ no family history of hypertension HbA1c ϭ hemoglobin A1c IR ϭ insulin resistance NE ϭ norepinephrine SNS ϭ sympathetic nervous system plasma insulin levels were highest in the group with combined FHϩ and BPE. From entry to year 10, mean plasma NE levels increased significantly in all four study groups, but the rises were greater in the BPE groups. In the FHϪ group, entry plasma NE was significantly higher in the BPE group (PϽ0.05) but was not different in the FHϩ group. At year 10, plasma NE levels were significantly higher in the BPE groups regardless of FH status (FHϪ, PϽ0.01; FHϩ, PϽ0.05; Figure 2 , bottom). Figure 3 shows that the increments and percent changes in insulin were higher in FHϩ regardless of changes in BP over time. In the FHϩ groups, insulin increments and percent changes were significantly greater in the BPE group (PϽ0.01 and PϽ0.01, respectively). Increments and percent changes in plasma NE were significantly higher in those with BPE whether FHϩ or FHϪ (Figure 3 ). In the groups in which BP did not rise, there was no difference in NE increments between FHϩ and FHϪ subjects. However, in the BPE groups, increments and percent changes in NE were greater in FHϩ than FHϪ.
Discussion
In a previous study of the same cohort of 1064 subjects, we reported that sympathetic hyperactivity precedes hyperinsulinemia and BPE in young, nonobese Japanese men. 9 The present report of the same population and study design examined the influence of FHϩ on these variables. To study FH, 507 subjects were excluded, leaving 557 in whom the effects of FH could be examined without confounding variables. In this population, there was a 16% incidence of FH, as verified by medical records or direct BP measurements in their parents. Importantly, the occurrence of BPE over a 10-year period was much higher (33%) in the FHϩ than in the FHϪ (16%) subjects. However, SNS hyperactivity, as indexed by plasma NE levels, contributed to BPE regardless of whether subjects were FHϩ or FHϪ. Insulin was also associated with BPE, but compared with NE, the insulin increments were always greater in FHϩ than in FHϪ groups. Thus, SNS hyperactivity may be a less genetically determined predictor of hypertension, whereas hyperinsulinemia is more genetically determined. These data also indicate that SNS activity may be more closely related to the early development of hypertension than to hyperinsulinemia and FH. These observations might imply that environmental rather than genetic factors play a greater role in the development of hypertension.
It should be noted that two important influences on BP, age and BMI, were matched at entry and remained comparable in each study group at year 10. Because BMI did not change, this study allows analysis of these neurogenic and metabolic variables on BP without the confounding effect of obesity. It can be concluded that obesity need not be a major prerequisite for BPE or for elevations in SNS and insulin. There is concern that plasma NE levels are merely a rough index of sympathetic nerve activity. However, in such a large population-based study as the present, more complex measures of SNS activity, such as microneurography and NE spillover, would not be feasible.
Several other studies have noted abnormal glucose and insulin metabolism in normotensive offspring of families with hypertension. Ferrari et al 20 reported IR, greater insulin responses to glucose, and dyslipidemia in young normotensive males who were FHϩ. Beaty et al 21 also found higher BP and IR in FHϩ offspring. Neutel et al 22 found higher insulin levels in normotensive individuals who were FHϩ. In that study as well as our present findings, FHϩ also predicted other risk factors, such as higher levels of NE, renin, and cholesterol. Facchini et al 23 noted greater insulin responses and IR in 38 normotensive subjects who were FHϩ. Ishibashi 24 found higher insulin levels in 152 FHϩ school-age girls compared with 131 FHϪ girls and noted an increased body weight in the FHϩ girls. Ionic risk factors may also be important because FHϩ with IR have abnormal erythrocyte Na ϩ transport 25 and higher platelet calcium levels. 26 One study included only lean normotensive subjects, suggesting, as in our study, that body weight may not be the major factor in the occurrence of metabolic abnormalities in FHϩ subjects. 25 The Heureka study of 11 001 participants reported that plasma insulin was correlated with BP in FHϩ subjects only. 27 One study noted higher levels of insulin and C peptide in both normotensive and essential hypertension subjects who were FHϩ. 28 A recent study from Mexico City concluded that IR in FHϩ subjects was more closely related to obesity than FH. 29 In general, most of these family studies offer strong evidence that young normotensive subjects who are FHϩ are at increased risk for BPE. These data also imply that hyperinsulinemia and IR precede the changes in BP. The majority of these studies were cross-sectional in data analysis. The present study differs from these reports because it presents the influence of FH on BPE and insulin with a longitudinal design and links the effects of SNS activity with the other variables.
We have also recently reported higher fasting and glucosestimulated insulin and NE levels in FHϩ compared with FHϪ subjects in three study groups: (1) normotensive subjects, (2) borderline hypertensives, and (3) established hypertensive subjects. 8 A positive family history of hypertension was defined as both parents having hypertension. This crosssectional study concluded that FHϩ could be an important determinant of SNS activity and insulin in all three BP-level groups but could differ in contribution, depending on the stage of BPE. Thus, in normotensive subjects, increased SNS seemed to be the major finding, whereas in borderline hypertensives, increases in SNS and insulin were noted concurrently. Our previous work has also shown that normotensive subjects with hyperinsulinemia have greater plasma NE levels than do those with normal insulin levels. 5 It is now well documented that vascular smooth muscle and the endothelium are insulin-sensitive tissues. Rowe et 12 al first showed that infusion of large doses of insulin increased plasma NE levels and BP in normal subjects. Anderson et al, 13, 14 using doses that were more physiological, found that insulin increased plasma NE but did not alter BP and reduced total peripheral resistance, suggesting an acute vasodilator effect. These studies suggest that if insulin affects BPE, it might do so through concomitant influences, such as genetic, metabolic, and neurogenic influences. Lembo et al 15 noted abnormal SNS overactivity evoked by insulin in the skeletal muscle of subjects with essential hypertension. In addition, both adrenergic and cholinergic blockade altered the effect of insulin on calf blood flow. 16 Of interest, infusion of insulin in subjects with established IR produces vasoconstriction rather than vasodilation.
17,18 Baron 19 demonstrated that the dosedependent effects of insulin to increased leg blood flow are markedly impaired in obesity and type 2 diabetes mellitus. These studies support the present findings that in young, normotensive, nonobese men, the greater rise in insulin levels over 10 years in the BPE groups could be contributing to their rise in BP.
It has been argued whether the initial event in BPE is hyperactivity of the SNS, which then leads to increased insulin and BP levels, or whether higher BP activates these systems. Julius et al 10, 11 have proposed that prolonged stimulation of the SNS leads to elevated BP and plasma insulin levels. This "chicken-and-egg" question can only be resolved in longitudinal studies such as the present report, wherein NE, insulin, and BP levels can be examined over time in normotensive subjects. In support of the findings of Julius et al, 10, 11 we reported that in initially normotensive subjects who had a BPE over 10 years, SNS hyperactivity preceded the emergence of hyperinsulinemia. 9 The present study links hyperinsulinemia and SNS hyperactivity to a family history of hypertension and BPE by use of a longitudinal design. The normotensive subjects with FHϩ had greater BP, fasting insulin, and NE levels at any time compared with FHϪ subjects. Furthermore, in FHϪ subjects, plasma NE levels at entry and the increments in plasma NE during 10 years were greater in subjects with BPE than in those without BPE. Also, higher BP levels were recorded at entry in FHϩ subjects with BPE. In contrast to NE and BP values, fasting plasma insulin levels at entry, increments in insulin, and percent increments in insulin over 10 years were similar between subjects with and without BPE in FHϪ subjects; however, in FHϩ subjects, these measures were greater in subjects with BPE than in those without BPE.
In summary, SNS hyperactivity is more closely related to BPE than are insulin levels or FHϩ in normotensive subjects. FHϩ appears to be more closely related to increases in insulin. SNS hyperactivity appears to play a greater role in the development of hypertension in an normotensive population compared with insulin or genetic influences.
